Drug Discovery Today

Article	Citations
Contents page 2	213
Contents page	201
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	186
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	179
New views on endothelial dysfunction in gestational hypertension and potential therapy targets	145
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	136
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	132
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	123
Tubulin targeting agents and their implications in non-cancer disease management	116
Gastroretentive drug delivery systems: A holy grail in oral delivery	112
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	106
General aspects of powder rheology applied to pharmaceutical formulations	106
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	103
The potential value of 5-androstenediol in countering acute radiation syndrome	100
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	100
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	98
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	95
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	88
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	87
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	85
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases	83
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	80
Antibody–drug conjugates: What drives their progress?	79
Specificity of pharmacokinetic modeling of nanomedicines	77
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	77

The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	77
Computational modeling approaches and regulatory pathways for drug combinations	75
Graph neural networks for automated de novo drug design	73
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	72
CIPDB: A biological structure databank for studying cation and π interactions	71
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	70
The recent progress of deep-learning-based in silico prediction of drug combination	70
Models and approaches to comprehend and address glial inflammation following spinal cord injury	69
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	69
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	68
Contents page 2	68
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	68
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	67
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	66
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	66
Targeted protein degradation: current molecular targets, localization, and strategies	65
Organoids in modelling infectious diseases	63
Benchmarking the mechanisms of frequent hitters: limitation of PAINS alerts	62
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	62
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	61
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	60
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	60
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	58
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	56
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	56
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	56
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	55
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	54
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	54
Molecular approaches for the treatment and prevention of Friedreich's ataxia	53
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	53
Pathogenic TDP-43 in amyotrophic lateral sclerosis	53
Biofilm control by ionic liquids	52
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	52
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	51
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	49
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	48
MRI assessment of cerebral perfusion in clinical trials	47
Caught between a ROCK and a hard place: current challenges in structure-based drug design	47
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	46
Overcoming the protein corona in chitosan-based nanoparticles	46
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	46
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	46
Recent advances towards overcoming the blood–brain barrier	45
Contents page 2	45
Steps toward nebulization in-use studies to understand the stability of new biological entities	45
Overview of new indications for novel drugs approved in China between 2018 and 2024	45
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	45
Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection	45
50 shades of AI in regulatory science	44

Recent advances in multitarget-directed ligands via in silico drug discovery	44
Global or local: The future of biotech	44
Opioid epidemic and the urge to discover new treatment options	44
IRE1α-mediated UPR activation in gastrointestinal cancers: Adaptive mechanisms and therapeutic potential	44
Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets	44
Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery	44
Contents page	43
Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis	43
Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches	43
Illuminating function of the understudied druggable kinome	42
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy	42
Elevating life science R&D success with AI: a framework	41
Open innovation: A paradigm shift in pharma R&D?	41
In silico resources help combat cancer drug resistance mediated by target mutations	41
The role of gut microbial β-glucuronidase in drug disposition and development	40
An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities	40
UCP1 activation: Hottest target in the thermogenesis pathway to treat obesity using molecules of synthetic and natural origin	40
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices	40
Quantum computing's potential for drug discovery: Early stage industry dynamics	39
Genetic–epigenetic targets for PCOS-associated diabesity	39
Renal cell carcinoma therapy: Current and new drug candidates	39
Drugs from drugs: New chemical insights into a mature concept	39
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease	39
Recent advances in dual-drug co-amorphous systems	38
Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases	38
Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus	38
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization	38
Pharmaceutical strategies for the treatment of bacterial biofilms in chronic wounds	38
Transforming patient engagement in clinical trials: Moving from a transactional relationship to human-centered care	37
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections	37
Metabophore-mediated retro-metabolic (‘MeMeReMe’) approach in drug design	37
Cubosome-based cosmeceuticals: A breakthrough in skincare	37
Strategizing the human microbiome for small molecules: Approaches and perspectives	36
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial	36
The Unitary Patent and UPC – Implications for the pharmaceutical sector	36
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy	36
Artificially engineered bacteria to treat gastrointestinal disease and cancer	35
Corrigendum to “Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors” [Drug Discov. Today 28(1) (2023) 103394]	35
Oncological drug discovery: AI meets structure-based computational research	35
Small molecules targeting canonical transient receptor potential channels: an update	35
Artificial intelligence methods in kinase target profiling: Advances and challenges	35
dbDNA™: An advanced platform for genetic medicines	35
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases	35
2023 in review: FDA approvals of new medicines	35
The expanding repertoire of covalent warheads for drug discovery	34
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates	34
Geometric deep learning methods and applications in 3D structure-based drug design	34
Corrigendum to “Role of transient receptor potential channels in the regulation of vascular tone” [Drug Discov. Today 29(7) (2024) 104051]	34
Approaches to advance drug discovery for neglected tropical diseases	34
Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches	33
Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation	33
Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy	33
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236	33
Compound–protein interaction prediction by deep learning: Databases, descriptors and models	33
Therapeutic targeting of the complement system in ocular disease	32
A new era for schizophrenia drug development – Lessons for the future	32
Molecular medicinal insights into scaffold hopping-based drug discovery success	32
Science of, and insights into, thermodynamic principles for dermal formulations	32
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery	32
Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections	32
Computational resources in the management of antibiotic resistance: Speeding up drug discovery	32
Druggable genome special issue: An introduction	32
Expanding therapeutic potential of Bdellovibrio bacteriovorus against multidrug-resistant pathogens	31
Harnessing personalized tailored medicines to digital-based data-enriched edible pharmaceuticals	31
Advancing ocular gene therapy: a machine learning approach to enhance delivery, uptake and gene expression	31
Contents page	31
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework	31
Corrigendum to “Critical path activities in clinical trial setup & conduct – How to avoid bottlenecks and accelerate clinical trials” [Drug Discov. Today 28(10) (2023) 103733]	31
Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview	31
The era of gene therapy: From preclinical development to clinical application	31
Corrigendum to “Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles” [Drug Discov. Today 28(6) (2023) 103600]	31
The importance of a go-to-market strategy in the commercialisation of cellular immunotherapies	31
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies	31
Targeting autophagy in colorectal cancer: An update on pharmacological small-molecule compounds	31
Peptide-derived ligands for the discovery of safer opioid analgesics	31
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs	31
A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023	31
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics	30
A pipeline analysis of advanced therapy medicinal products	30
‘Home inspections’ for life sciences companies going public before clinical proof-of-concept	30

Publisher’s Note	30
RhoA activation-mediated vascular permeability in capillary malformation-arteriovenous malformation syndrome: a hypothesis	30
Social media mining in drug development—Fundamentals and use cases	30
Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review	30
Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe	29
Early career researchers’ experiences in drug discovery in Africa	29
Orphan GPR52 as an emerging neurotherapeutic target	29
Nanomedicine approaches to reduce cytokine storms in severe infections	29
Using computers to ESKAPE the antibiotic resistance crisis	29
Regulating NETosis: An emerging facet of statin pleiotropy	29
IdopNetwork as a genomic predictor of drug response	29
Drugging the entire human proteome: Are we there yet?	29
Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonosis	28
Chiral-engineered supraparticles: Emerging tools for drug delivery	28
Targeting SIRT1-regulated autophagic cell death as a novel therapeutic avenue for cancer prevention	28
Deadly interactions: Synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics	28
TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology	28
Translating precision medicine for autism spectrum disorder: A pressing need	28
Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy	28
Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer	28
Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications	28
Evaluating the performance of drug-repurposing technologies	27
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery	27
Effectiveness of histamine receptor antagonists in the treatment of histamine-driven clinical symptoms: do we have a histamine or, better, an anti-histamine problem?	27
Peptide modulators of cell migration: Overview, applications and future development	27
Spare and repair the gut microbiota from antibiotic-induced dysbiosis: state-of-the-art	27
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease	27
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	27
A personalized pharmaco-epistatic network model of precision medicine	27
Nanophotonic waveguide-based sensing of circulating cell-free mitochondrial DNA: implications for personalized medicine	27
Recent progress in covalent organic frameworks for cancer therapy	27
Therapies for Inherited Retinal Dystrophies: What is Enough?	27
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	26
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	26
Can preclinical drug development help to predict adverse events in clinical trials?	26
Which cryptic sites are feasible drug targets?	26
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	26
Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016–2024 regulatory review	26
Web resources facilitate drug discovery in treatment of COVID-19	26
Patents, trade secrets and pricing	26
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	26
Optical tweezers for drug discovery	26
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	26
Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern	26
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	26
Prospects of halofuginone as an antiprotozoal drug scaffold	25
Concepts and applications of chemical fingerprint for hit and lead screening	25
Novel and investigational therapies for wet and dry age-related macular degeneration	25
Applications of density functional theory in COVID-19 drug modeling	25
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer	25
Nanofibers as drug-delivery systems for antimicrobial peptides	25
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	25
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	25
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	25
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	25
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	25
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	25
ATP-binding cassette efflux transporters and MDR in cancer	25
Electron diffraction: Accelerating drug development	25
Contents page	24
Corrigendum to ‘Synthetic lethality: a step forward for personalized medicine in cancer’ [Drug Discov. Today 25 (2020) 305–320]	24
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment	24
Informatic challenges and advances in illuminating the druggable proteome	24
New approaches for challenging therapeutic targets	24
Extrapolation: Experience gained from original biologics	24
Contents page	24
Metallocompounds as anticancer agents against osteosarcoma	24
Treating liver cancer through arginine depletion	24
Contents page	24
How can MSI enhance our understanding of ASO distribution?	24
Dual-action potential of cationic cryptides against infections and cancers	24
DDR1-targeted therapies: current limitations and future potential	24
Rapid progress in neuroimaging technologies fuels central nervous system translational medicine	24
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy	23
On the pivotal role of drug discovery in sustainable EU pharma reform	23
Pivotal role of nitrogen heterocycles in Alzheimer’s disease drug discovery	23
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2	23
Unleashing the power of generative AI in drug discovery	23
Positron emission tomographic imaging in drug discovery	23
Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?	23
Pharmaceutical nanocrystals: A promising approach for improved topical drug delivery	23
Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis	23
Illuminating the druggable genome: Pathways to progress	23
Statins and angiogenesis in non-cardiovascular diseases	23
Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer	23
How missing value imputation is confounded with batch effects and what you can do about it	23
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation	23
The forced swim test has poor accuracy for identifying novel antidepressants	23
Tracing drugs from discovery to disposal	22
The Wnt signaling cascade: a potential but untapped therapeutic target for monkeypox infection	22
Kinase signaling as a drug target modality for regulation of vascular hyperpermeability: A case for ARDS therapy development	22
Organoid and microfluidics-based platforms for drug screening in COVID-19	22
Advances in antibody phage display technology	22
How to build a tumor: An industry perspective	22
Artificial intelligence for RNA–ligand interaction prediction: advances and prospects	22